_id
691b08583c536f8df2318964
Ticker
AELIS.PA
Name
Aelis Farma SA
Exchange
PA
Address
1 rue Lafaurie de Monbadon, Bordeaux, France, 33 000
Country
France
Sector
Healthcare
Industry
Biotechnology
Currency
EUR
Website
https://www.aelisfarma.com
Description
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase II clinical trials to treat cognitive deficits observed in down syndrome, as well as other cognitive impairments. Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France.
Last Close
1.12
Volume
13066
Current Price
1.145
Change
0
Last Updated
2025-12-30T12:32:43.285Z
Image
https://logo.clearbit.com/www.aelisfarma.com
Ipo Date
-
Market Cap
15252271
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
4
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-06-30
Revenue
895000
Cost Of Revenue
131000
Gross Profit
895000
Operating Expenses
5039999
Operating Income
-4144999
Interest Expense
131000
Pretax Income
-4319000
Net Income
-4323000
Eps
-0.3163323419928001
Dividends Per Share
-
Shares Outstanding
13618098
Income Tax Expense
4000
EBITDA
-4103500
Operating Margin
-463.12837988826817
Total Other Income Expense Net
-174000
Cash
10791000
Short Term Investments
-
Receivables
12000
Inventories
-
Total Current Assets
14117000
Property Plant Equipment
1203000
Total Assets
15579000
Payables
1032999
Short Term Debt
2050000
Long Term Debt
-
Total Liabilities
9465000
Equity
6114000
Bs_currency_symbol
-
Depreciation
42500
Change In Working Capital
369000
Cash From Operations
-3883000
Capital Expenditures
6000
Cash From Investing
-6000
Cash From Financing
771000
Net Change In Cash
-3260000
Cf_currency_symbol
-
PE
-
PB
2.5593029138043835
ROE
-70.70657507360157
ROA
-27.748892740227227
FCF
-3889000
Fcf Percent
-4.345251396648044
Piotroski FScore
1
Health Score
25
Deep Value Investing Score
3
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
1.5
Growth Investing Score
1
Momentum Investing Score
5
Net Net Investing Score
3
Quality Investing Score
1.5
Value Investing Score
3
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
895000
Quarters > 0 > income Statement > cost Of Revenue
131000
Quarters > 0 > income Statement > gross Profit
895000
Quarters > 0 > income Statement > operating Expenses
5039999
Quarters > 0 > income Statement > operating Income
-4144999
Quarters > 0 > income Statement > interest Expense
131000
Quarters > 0 > income Statement > pretax Income
-4319000
Quarters > 0 > income Statement > net Income
-4323000
Quarters > 0 > income Statement > eps
-0.3163323419928001
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
13666007
Quarters > 0 > income Statement > income Tax Expense
4000
Quarters > 0 > income Statement > EBITDA
-4103500
Quarters > 0 > income Statement > operating Margin
-463.12837988826817
Quarters > 0 > income Statement > total Other Income Expense Net
-174000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
10791000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
12000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
14117000
Quarters > 0 > balance Sheet > property Plant Equipment
1203000
Quarters > 0 > balance Sheet > total Assets
15579000
Quarters > 0 > balance Sheet > payables
1032999
Quarters > 0 > balance Sheet > short Term Debt
2050000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
9465000
Quarters > 0 > balance Sheet > equity
6114000
Quarters > 0 > balance Sheet > currency_symbol
-
Quarters > 0 > cash Flow > net Income
-4323000
Quarters > 0 > cash Flow > depreciation
42500
Quarters > 0 > cash Flow > change In Working Capital
369000
Quarters > 0 > cash Flow > cash From Operations
-3883000
Quarters > 0 > cash Flow > capital Expenditures
6000
Quarters > 0 > cash Flow > cash From Investing
-6000
Quarters > 0 > cash Flow > cash From Financing
771000
Quarters > 0 > cash Flow > net Change In Cash
-3260000
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.3163323419928001
Quarters > 0 > ratios > PB
2.5593029138043835
Quarters > 0 > ratios > ROE
-70.70657507360157
Quarters > 0 > ratios > ROA
-27.748892740227227
Quarters > 0 > ratios > FCF
-3889000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-4.345251396648044
Quarters > 0 > health Score
25
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
1438000
Quarters > 1 > income Statement > cost Of Revenue
3330000
Quarters > 1 > income Statement > gross Profit
1438000
Quarters > 1 > income Statement > operating Expenses
5508000
Quarters > 1 > income Statement > operating Income
-4070000
Quarters > 1 > income Statement > interest Expense
121000
Quarters > 1 > income Statement > pretax Income
1336000
Quarters > 1 > income Statement > net Income
-3873000
Quarters > 1 > income Statement > eps
-0.2826000046844617
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
13704883
Quarters > 1 > income Statement > income Tax Expense
8000
Quarters > 1 > income Statement > EBITDA
-4458000
Quarters > 1 > income Statement > operating Margin
-283.03198887343535
Quarters > 1 > income Statement > total Other Income Expense Net
5406000
Quarters > 1 > income Statement > currency_symbol
EUR
Quarters > 1 > balance Sheet > cash
14051000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
2462000
Quarters > 1 > balance Sheet > inventories
0
Quarters > 1 > balance Sheet > total Current Assets
18126000
Quarters > 1 > balance Sheet > property Plant Equipment
1336000
Quarters > 1 > balance Sheet > total Assets
19706000
Quarters > 1 > balance Sheet > payables
1181000
Quarters > 1 > balance Sheet > short Term Debt
1645000
Quarters > 1 > balance Sheet > long Term Debt
3690000
Quarters > 1 > balance Sheet > total Liabilities
9590000
Quarters > 1 > balance Sheet > equity
10116000
Quarters > 1 > balance Sheet > currency_symbol
EUR
Quarters > 1 > cash Flow > net Income
-3873000
Quarters > 1 > cash Flow > depreciation
140000
Quarters > 1 > cash Flow > change In Working Capital
-622000
Quarters > 1 > cash Flow > cash From Operations
-3471000
Quarters > 1 > cash Flow > capital Expenditures
25000
Quarters > 1 > cash Flow > cash From Investing
-25000
Quarters > 1 > cash Flow > cash From Financing
4906000
Quarters > 1 > cash Flow > net Change In Cash
1466000
Quarters > 1 > cash Flow > currency_symbol
EUR
Quarters > 1 > ratios > PE
-0.2826000046844617
Quarters > 1 > ratios > PB
1.5512150093910637
Quarters > 1 > ratios > ROE
-38.2858837485172
Quarters > 1 > ratios > ROA
-19.65391251395514
Quarters > 1 > ratios > FCF
-3496000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-2.43115438108484
Quarters > 1 > health Score
31
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
4123998
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
4123998
Quarters > 2 > income Statement > operating Expenses
7788998
Quarters > 2 > income Statement > operating Income
-3665000
Quarters > 2 > income Statement > interest Expense
104000
Quarters > 2 > income Statement > pretax Income
-8784000
Quarters > 2 > income Statement > net Income
-3583000
Quarters > 2 > income Statement > eps
-0.27095248001678196
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
13223721
Quarters > 2 > income Statement > income Tax Expense
-5201000
Quarters > 2 > income Statement > EBITDA
-3538000
Quarters > 2 > income Statement > operating Margin
-88.87007219693123
Quarters > 2 > income Statement > total Other Income Expense Net
-5119000
Quarters > 2 > income Statement > currency_symbol
EUR
Quarters > 2 > balance Sheet > cash
12585000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
4400000
Quarters > 2 > balance Sheet > inventories
-2881000
Quarters > 2 > balance Sheet > total Current Assets
18758000
Quarters > 2 > balance Sheet > property Plant Equipment
1451000
Quarters > 2 > balance Sheet > total Assets
20471000
Quarters > 2 > balance Sheet > payables
3399000
Quarters > 2 > balance Sheet > short Term Debt
1211000
Quarters > 2 > balance Sheet > long Term Debt
2874000
Quarters > 2 > balance Sheet > total Liabilities
10527000
Quarters > 2 > balance Sheet > equity
9944000
Quarters > 2 > balance Sheet > currency_symbol
EUR
Quarters > 2 > cash Flow > net Income
-3583000
Quarters > 2 > cash Flow > depreciation
256000
Quarters > 2 > cash Flow > change In Working Capital
-4344000
Quarters > 2 > cash Flow > cash From Operations
-8177000
Quarters > 2 > cash Flow > capital Expenditures
165000
Quarters > 2 > cash Flow > cash From Investing
-165000
Quarters > 2 > cash Flow > cash From Financing
719000
Quarters > 2 > cash Flow > net Change In Cash
-7645000
Quarters > 2 > cash Flow > currency_symbol
EUR
Quarters > 2 > ratios > PE
-0.27095248001678196
Quarters > 2 > ratios > PB
1.5226428544851167
Quarters > 2 > ratios > ROE
-36.031777956556716
Quarters > 2 > ratios > ROA
-17.50280885154609
Quarters > 2 > ratios > FCF
-8342000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-2.0227943854482957
Quarters > 2 > health Score
24
Quarters > 3 > quarter
2024-03-31
Quarters > 3 > income Statement > revenue
2061999
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
2061999
Quarters > 3 > income Statement > operating Expenses
3894499
Quarters > 3 > income Statement > operating Income
-1832500
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-1791500
Quarters > 3 > income Statement > net Income
-1791500
Quarters > 3 > income Statement > eps
-0.13547624000839098
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
13223721
Quarters > 3 > income Statement > income Tax Expense
-500
Quarters > 3 > income Statement > EBITDA
-1769000
Quarters > 3 > income Statement > operating Margin
-88.87007219693123
Quarters > 3 > income Statement > total Other Income Expense Net
41000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
12585000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
1519000
Quarters > 3 > balance Sheet > inventories
1769000
Quarters > 3 > balance Sheet > total Current Assets
18758000
Quarters > 3 > balance Sheet > property Plant Equipment
1451000
Quarters > 3 > balance Sheet > total Assets
20471000
Quarters > 3 > balance Sheet > payables
3399000
Quarters > 3 > balance Sheet > short Term Debt
1211000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
10527000
Quarters > 3 > balance Sheet > equity
9944000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-1791500
Quarters > 3 > cash Flow > depreciation
64000
Quarters > 3 > cash Flow > change In Working Capital
-2172000
Quarters > 3 > cash Flow > cash From Operations
-4088500
Quarters > 3 > cash Flow > capital Expenditures
82500
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
359500
Quarters > 3 > cash Flow > net Change In Cash
-3813500
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-0.13547624000839098
Quarters > 3 > ratios > PB
1.5226428544851167
Quarters > 3 > ratios > ROE
-18.015888978278358
Quarters > 3 > ratios > ROA
-8.751404425773044
Quarters > 3 > ratios > FCF
-4171000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-2.0227943854482957
Quarters > 3 > health Score
24
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
2678000
Annuals > 0 > income Statement > cost Of Revenue
5562000
Annuals > 0 > income Statement > gross Profit
2678000
Annuals > 0 > income Statement > operating Expenses
13297000
Annuals > 0 > income Statement > operating Income
-7735000
Annuals > 0 > income Statement > interest Expense
206000
Annuals > 0 > income Statement > pretax Income
-7448000
Annuals > 0 > income Statement > net Income
-7456000
Annuals > 0 > income Statement > eps
-0.544000014008584
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
13705882
Annuals > 0 > income Statement > income Tax Expense
8000
Annuals > 0 > income Statement > EBITDA
-8618000
Annuals > 0 > income Statement > operating Margin
-288.83495145631065
Annuals > 0 > income Statement > total Other Income Expense Net
287000
Annuals > 0 > income Statement > currency_symbol
EUR
Annuals > 0 > balance Sheet > cash
14051000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
2462000
Annuals > 0 > balance Sheet > inventories
0
Annuals > 0 > balance Sheet > total Current Assets
18126000
Annuals > 0 > balance Sheet > property Plant Equipment
1336000
Annuals > 0 > balance Sheet > total Assets
19706000
Annuals > 0 > balance Sheet > payables
1181000
Annuals > 0 > balance Sheet > short Term Debt
1645000
Annuals > 0 > balance Sheet > long Term Debt
3690000
Annuals > 0 > balance Sheet > total Liabilities
9590000
Annuals > 0 > balance Sheet > equity
10116000
Annuals > 0 > balance Sheet > currency_symbol
EUR
Annuals > 0 > cash Flow > net Income
-7456000
Annuals > 0 > cash Flow > depreciation
268000
Annuals > 0 > cash Flow > change In Working Capital
-4966000
Annuals > 0 > cash Flow > cash From Operations
-11831000
Annuals > 0 > cash Flow > capital Expenditures
190000
Annuals > 0 > cash Flow > cash From Investing
-190000
Annuals > 0 > cash Flow > cash From Financing
5808000
Annuals > 0 > cash Flow > net Change In Cash
-6160000
Annuals > 0 > cash Flow > currency_symbol
EUR
Annuals > 0 > ratios > PE
-0.544000014008584
Annuals > 0 > ratios > PB
1.5174562910241203
Annuals > 0 > ratios > ROE
-73.70502174772638
Annuals > 0 > ratios > ROA
-37.836192022734195
Annuals > 0 > ratios > FCF
-12021000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-4.488797610156833
Annuals > 0 > health Score
30
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
9054000
Annuals > 1 > income Statement > cost Of Revenue
-3304000
Annuals > 1 > income Statement > gross Profit
9054000
Annuals > 1 > income Statement > operating Expenses
18819000
Annuals > 1 > income Statement > operating Income
-6461000
Annuals > 1 > income Statement > interest Expense
157000
Annuals > 1 > income Statement > pretax Income
-5075000
Annuals > 1 > income Statement > net Income
-5078000
Annuals > 1 > income Statement > eps
-0.39368049006166084
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
12898785
Annuals > 1 > income Statement > income Tax Expense
3000
Annuals > 1 > income Statement > EBITDA
-6347000
Annuals > 1 > income Statement > operating Margin
-71.36072454163906
Annuals > 1 > income Statement > total Other Income Expense Net
1386000
Annuals > 1 > income Statement > currency_symbol
EUR
Annuals > 1 > balance Sheet > cash
20230000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
1903000
Annuals > 1 > balance Sheet > inventories
53000
Annuals > 1 > balance Sheet > total Current Assets
24870000
Annuals > 1 > balance Sheet > property Plant Equipment
1183000
Annuals > 1 > balance Sheet > total Assets
26281000
Annuals > 1 > balance Sheet > payables
4495000
Annuals > 1 > balance Sheet > short Term Debt
1094000
Annuals > 1 > balance Sheet > long Term Debt
2049000
Annuals > 1 > balance Sheet > total Liabilities
13080000
Annuals > 1 > balance Sheet > equity
13201000
Annuals > 1 > balance Sheet > currency_symbol
EUR
Annuals > 1 > cash Flow > net Income
-5078000
Annuals > 1 > cash Flow > depreciation
168000
Annuals > 1 > cash Flow > change In Working Capital
-7677000
Annuals > 1 > cash Flow > cash From Operations
-12586000
Annuals > 1 > cash Flow > capital Expenditures
88000
Annuals > 1 > cash Flow > cash From Investing
-88000
Annuals > 1 > cash Flow > cash From Financing
-1341000
Annuals > 1 > cash Flow > net Change In Cash
-14185000
Annuals > 1 > cash Flow > currency_symbol
EUR
Annuals > 1 > ratios > PE
-0.39368049006166084
Annuals > 1 > ratios > PB
1.0943594576168474
Annuals > 1 > ratios > ROE
-38.46678281948338
Annuals > 1 > ratios > ROA
-19.321943609451694
Annuals > 1 > ratios > FCF
-12674000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-1.3998232825270598
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
3809000
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
3809000
Annuals > 2 > income Statement > operating Expenses
12333000
Annuals > 2 > income Statement > operating Income
-8525000
Annuals > 2 > income Statement > interest Expense
112000
Annuals > 2 > income Statement > pretax Income
-14287000
Annuals > 2 > income Statement > net Income
-14288000
Annuals > 2 > income Statement > eps
-1.2067576740556645
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
11839991
Annuals > 2 > income Statement > income Tax Expense
1000
Annuals > 2 > income Statement > EBITDA
-16227000
Annuals > 2 > income Statement > operating Margin
-223.81202415332106
Annuals > 2 > income Statement > total Other Income Expense Net
-5762000
Annuals > 2 > income Statement > currency_symbol
EUR
Annuals > 2 > balance Sheet > cash
34396000
Annuals > 2 > balance Sheet > short Term Investments
35000
Annuals > 2 > balance Sheet > receivables
1369000
Annuals > 2 > balance Sheet > inventories
35000
Annuals > 2 > balance Sheet > total Current Assets
38602000
Annuals > 2 > balance Sheet > property Plant Equipment
177000
Annuals > 2 > balance Sheet > total Assets
39218000
Annuals > 2 > balance Sheet > payables
2415000
Annuals > 2 > balance Sheet > short Term Debt
816000
Annuals > 2 > balance Sheet > long Term Debt
1384000
Annuals > 2 > balance Sheet > total Liabilities
19428000
Annuals > 2 > balance Sheet > equity
19790000
Annuals > 2 > balance Sheet > currency_symbol
EUR
Annuals > 2 > cash Flow > net Income
-14288000
Annuals > 2 > cash Flow > depreciation
70000
Annuals > 2 > cash Flow > change In Working Capital
-3402000
Annuals > 2 > cash Flow > cash From Operations
-13051000
Annuals > 2 > cash Flow > capital Expenditures
137000
Annuals > 2 > cash Flow > cash From Investing
-86000
Annuals > 2 > cash Flow > cash From Financing
22097000
Annuals > 2 > cash Flow > net Change In Cash
9686000
Annuals > 2 > cash Flow > currency_symbol
EUR
Annuals > 2 > ratios > PE
-1.2067576740556645
Annuals > 2 > ratios > PB
0.6700752865083376
Annuals > 2 > ratios > ROE
-72.19807983830218
Annuals > 2 > ratios > ROA
-36.432250497220664
Annuals > 2 > ratios > FCF
-13188000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-3.462326069834602
Annuals > 2 > health Score
29
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
9075000
Annuals > 3 > income Statement > cost Of Revenue
-
Annuals > 3 > income Statement > gross Profit
9075000
Annuals > 3 > income Statement > operating Expenses
6524000
Annuals > 3 > income Statement > operating Income
2552000
Annuals > 3 > income Statement > interest Expense
140000
Annuals > 3 > income Statement > pretax Income
1759000
Annuals > 3 > income Statement > net Income
574000
Annuals > 3 > income Statement > eps
0.05983684348349671
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
9592752
Annuals > 3 > income Statement > income Tax Expense
1185000
Annuals > 3 > income Statement > EBITDA
844000
Annuals > 3 > income Statement > operating Margin
28.121212121212118
Annuals > 3 > income Statement > total Other Income Expense Net
-793000
Annuals > 3 > income Statement > currency_symbol
EUR
Annuals > 3 > balance Sheet > cash
24710000
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
1611000
Annuals > 3 > balance Sheet > inventories
17000
Annuals > 3 > balance Sheet > total Current Assets
28027000
Annuals > 3 > balance Sheet > property Plant Equipment
196000
Annuals > 3 > balance Sheet > total Assets
28313000
Annuals > 3 > balance Sheet > payables
2243000
Annuals > 3 > balance Sheet > short Term Debt
1156000
Annuals > 3 > balance Sheet > long Term Debt
3262000
Annuals > 3 > balance Sheet > total Liabilities
27415000
Annuals > 3 > balance Sheet > equity
899000
Annuals > 3 > balance Sheet > currency_symbol
EUR
Annuals > 3 > cash Flow > net Income
574000
Annuals > 3 > cash Flow > depreciation
35000
Annuals > 3 > cash Flow > change In Working Capital
16383000
Annuals > 3 > cash Flow > cash From Operations
18970000
Annuals > 3 > cash Flow > capital Expenditures
213000
Annuals > 3 > cash Flow > cash From Investing
-212000
Annuals > 3 > cash Flow > cash From Financing
180000
Annuals > 3 > cash Flow > net Change In Cash
20172000
Annuals > 3 > cash Flow > currency_symbol
EUR
Annuals > 3 > ratios > PE
0.05983684348349671
Annuals > 3 > ratios > PB
11.95092573971079
Annuals > 3 > ratios > ROE
63.84872080088988
Annuals > 3 > ratios > ROA
2.027337265567054
Annuals > 3 > ratios > FCF
18757000
Annuals > 3 > ratios > Piotroski FScore
3
Annuals > 3 > ratios > fcf Percent
2.0668870523415976
Annuals > 3 > health Score
59
Valuation > metrics > PE
-0.3163323419928001
Valuation > metrics > PB
2.5593029138043835
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-70.70657507360157
Profitability > metrics > ROA
-30.62265353828717
Profitability > metrics > Net Margin
-4.830167597765363
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
1.5480863591756624
Risk > metrics > Interest Coverage
-31.641213740458014
Risk > final Score
-97
Risk > verdict
High
Liquidity > metrics > Current Ratio
4.578982996750891
Liquidity > metrics > Quick Ratio
4.578982996750891
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
80
Prev Valuations > 2
80
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-87
Prev Risks > 1
-111
Prev Risks > 2
-296
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T23:08:27.004Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-31
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-09-22
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.32
Earnings History > 1 > eps Estimate
0
Earnings History > 1 > eps Difference
-0.32
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-04-29
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.28
Earnings History > 2 > eps Estimate
0
Earnings History > 2 > eps Difference
-0.28
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2023-03-31
Earnings History > 3 > report Date
2023-04-03
Earnings History > 3 > date
2023-03-31
Earnings History > 3 > before After Market
AfterMarket
Earnings History > 3 > currency
EUR
Earnings History > 3 > eps Actual
-0.28
Earnings History > 3 > eps Estimate
0
Earnings History > 3 > eps Difference
-0.28
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2022-06-30
Earnings History > 4 > report Date
2022-09-26
Earnings History > 4 > date
2022-06-30
Earnings History > 4 > before After Market
AfterMarket
Earnings History > 4 > currency
EUR
Earnings History > 4 > eps Actual
-0.93
Earnings History > 4 > eps Estimate
0
Earnings History > 4 > eps Difference
-0.93
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2022-03-31
Earnings History > 5 > report Date
2022-04-26
Earnings History > 5 > date
2022-03-31
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
EUR
Earnings History > 5 > eps Actual
-0.26
Earnings History > 5 > eps Estimate
0
Earnings History > 5 > eps Difference
-0.26
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2021-12-31
Earnings History > 6 > report Date
2022-02-03
Earnings History > 6 > date
2021-12-31
Earnings History > 6 > before After Market
AfterMarket
Earnings History > 6 > currency
EUR
Earnings History > 6 > eps Actual
-0.11
Earnings History > 6 > eps Estimate
0
Earnings History > 6 > eps Difference
-0.11
Earnings History > 6 > surprise Percent
-
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase II clinical trials to treat cognitive deficits observed in down syndrome, as well as other cognitive impairments. Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France.
Stock Price
€0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AAelis Farma Obtains Regulatory Approval of the Phase 2B Trial With AEF0217 in People With Down Syndrome Yahoo Finance
Read more →Showing 2 of 6
(Last Updated 2025-06-30)
Rating:
BUY
$
Analyst Picks
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Aelis Farma SA
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
—
Date
2025-06-30
EPS Actual
-0.32
EPS Estimate
0
EPS Difference
-0.32
Surprise Percent
0%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
€ 0
Cost Of Revenue
€ 0
Gross Profit
€ 0
Operating Expenses
€ 0
Operating Income
€ 0
Interest Expense
€ 0
Pretax Income
€ 0
Net Income
€ 0
Income Tax Expense
€ 0
EBITDA
€ 0
Total Other Income Expense Net
€ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
€ 0
Short Term Investments
€ 0
Receivables
€ 0
Inventories
€ 0
Total Current Assets
€ 0
Property Plant Equipment
€ 0
Total Assets
€ 0
Payables
€ 0
Short Term Debt
€ 0
Long Term Debt
€ 0
Total Liabilities
€ 0
Equity
€ 0
(Last Updated 2025-06-30)
Net Income
€ 0
Depreciation
€ 0
Change In Working Capital
€ 0
Cash From Operations
€ 0
Capital Expenditures
€ 0
Cash From Investing
€ 0
Cash From Financing
€ 0
Net Change In Cash
€ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.